The cell and gene therapy market has shown remarkable growth in 2024, with global market size reaching $21.28 billion and projected to hit $117.46 billion by 2034. Despite challenges, the sector has attracted significant investments, with $10.9 billion raised in the first half of 2024, while also experiencing evolving hiring trends and advancements in clinical trials across key regions.
Cell and Gene Therapy Market Growth
The cell and gene therapy sector has experienced robust expansion in 2024, with the global market size reaching $21.28 billion.
This growth trajectory is expected to continue, with projections indicating a market value of $117.46 billion by 2034, representing a compound annual growth rate (CAGR) of 18.6%. North America remains the dominant player, accounting for over 50% of the market share, with the U.S. market alone estimated at $8.48 billion in 2023 and forecasted to reach $55.47 billion by 2034.
Key Hiring Trends and Roles
Management positions dominated the hiring landscape in 2024, accounting for 27% of cell and gene therapy-related job postings globally, followed by life sciences roles at 23% and technical healthcare positions at 3%.
The United States led in recruitment activity, with 76.81% of new job postings in Q2 2024, while India and the UK followed with 5.6% and 3.8% respectively. Highly sought-after roles included researchers specializing in gene editing tools like CRISPR, manufacturing associates for drug production, AI specialists for drug discovery, and microbiologists for microbiome-focused diagnostics. Despite the growth, the industry continues to face skill gaps, particularly in specialized areas such as CRISPR technology and gene editing.
Investments and Regional Insights
In 2024, the cell and gene therapy sector saw a resurgence in investments, with the UK experiencing an increase from £0.77 billion to £0.97 billion in the financial year ending March 2024.
Notable funding rounds included ArsenalBio’s $325 million Series C for CAR-T therapies and Capstan Therapeutics’ $175 million Series B. The global landscape for clinical trials expanded, with North America leading in cancer and rare disease studies, while Asia-Pacific gained prominence for its streamlined regulatory processes and efficient patient recruitment. Europe continued to innovate through cross-border collaborations, focusing on accelerating therapy approvals and maintaining its competitive edge in the rapidly evolving market.
Challenges in the Sector
Despite the sector’s growth, several challenges emerged in 2024. A notable slowdown in IPOs and venture capital funding for early-stage startups occurred, potentially impacting innovation.
High interest rates also affected investment flows, creating a more cautious financial environment. The industry continued to grapple with significant skill shortages, particularly in specialized areas like gene editing, which could hinder rapid advancement and scaling of therapies. These challenges underscore the need for strategic planning and targeted initiatives to maintain the momentum in this transformative field.
Career Opportunities and Hubs
The cell and gene therapy market offers diverse career opportunities across research, development, manufacturing, and regulatory affairs. Key roles include research scientists, process development engineers, quality control specialists, and regulatory affairs managers.
To enter this field, a strong background in life sciences, bioengineering, or related disciplines is essential, with advanced degrees often preferred for specialized positions. Professionals are drawn to this sector due to its potential for groundbreaking medical advancements and the opportunity to make a significant impact on patient lives. The field’s rapid growth also promises career stability and advancement opportunities. Global hubs for cell and gene therapy include:
- Stevenage, UK: Home to the largest cluster in Europe and third-largest globally
- Boston and San Francisco, USA: Leading centers for biotech innovation and investment
- Shanghai, China: Emerging as a key player in Asia’s cell and gene therapy landscape
These hubs offer proximity to cutting-edge research institutions, industry leaders, and robust funding ecosystems, providing fertile ground for career growth and innovation in cell and gene therapies.
Emerging Technologies in Cell and Gene Therapy
The cell and gene therapy field is witnessing rapid technological advancements in 2024, with several innovative approaches emerging:
- CRISPR gene editing: Researchers are developing more precise and efficient CRISPR systems, such as the SpOT-ON enzyme, which offers enhanced specificity for target sites in the genome. This technology has shown promise in preclinical studies for treating conditions like hypercholesterolemia.
- Mechanical cell opening: A novel technology developed by researchers at the University of York uses mechanical forces to deliver gene-modifying tools to cells without damaging them. This approach, being commercialized by ForCell, could make gene therapies more accessible and cost-effective.
- CAR-T cell improvements: Scientists are working on enhancing CAR T-cell therapies by developing new screening methods to identify more effective and long-lasting cells against cancer. This includes exploring receptors from other immune cells, such as the B-cell receptor BAFF-R, to improve T-cell efficacy.
These emerging technologies are driving the field forward, potentially expanding the range of treatable conditions and improving the safety and efficacy of cell and gene therapies.
Regulatory Challenges and Breakthroughs in 2024
The regulatory landscape for cell and gene therapies (CGTs) in 2024 has been marked by significant challenges and breakthroughs. The FDA has approved four CGTs this year, with at least seven additional products expected to receive approval by year’s end.
This accelerated approval rate reflects the agency’s efforts to streamline the regulatory process for these innovative therapies.Key regulatory developments include:
- Increased flexibility in confirmatory trials for RMAT-designated therapies, allowing sponsors to use continued follow-up from pivotal trials rather than conducting additional studies.
- The UK’s Innovative Licencing and Access Pathway (ILAP) has reduced time to market access, exemplified by the UK becoming the first country to approve Casgevy in 2023.
- Challenges persist in adapting conventional regulatory requirements to CGTs, particularly regarding product quality, viability, and post-approval studies.
- The FDA’s Center for Biologics Evaluation and Research (CBER) is focusing on collaboration and innovation to accelerate the development and approval of transformative therapies.
These developments highlight the evolving regulatory framework aimed at fostering innovation while ensuring safety and efficacy in the rapidly advancing field of cell and gene therapies.
2025 Market Outlook
The cell and gene therapy market has demonstrated remarkable resilience and growth in 2024, setting the stage for an exciting 2025. Despite economic headwinds, the sector attracted $10.9 billion in investments during the first half of 2024, surpassing 2019’s total.
This robust financial backing, coupled with technological advancements and regulatory progress, positions the industry for continued expansion.Looking ahead to 2025, several trends are likely to shape the landscape:
- Increased approvals: Forecasts suggest a fourfold increase in CGT approvals in 2024, with expectations of a tenfold increase by 20272. This acceleration will likely continue into 2025, bringing more innovative therapies to market.
- Manufacturing advancements: The global market for automated and closed cell therapy is projected to reach $5.3 billion by 2029, with significant growth expected in 2025. This will address current manufacturing challenges and potentially reduce costs.
- Emerging markets: While North America remains dominant, emerging markets, particularly in Asia-Pacific, are poised for rapid growth in 2025, offering new opportunities for expansion and collaboration.
- Focus on commercial viability: As the market matures, there will be an increased emphasis on addressing the commercial viability gap, with efforts to streamline manufacturing processes and improve reimbursement strategies.
As the field continues to evolve, 2025 promises to be a pivotal year for cell and gene therapies, with potential breakthroughs in treatment options and market accessibility.
Stirling Q&R Recruitment Services
As the cell and gene therapy market continues to expand in 2025, companies will face increasing demand for skilled professionals in quality assurance and regulatory affairs. Stirling Q&R, a specialized recruitment firm, is well-positioned to support organizations in meeting these hiring challenges across the US and Europe.
With expertise in connecting top talent with roles in pharmaceutical, biotechnology, and medical device industries, Stirling Q&R offers tailored recruitment solutions for both permanent and contract positions.For companies looking to strengthen their quality and regulatory teams in 2025, Stirling Q&R provides:
- Access to a wide network of qualified candidates, from entry-level to executive positions
- In-depth understanding of industry-specific requirements and regulations
- Flexibility in hiring options, catering to both long-term strategic needs and short-term project demands
- Expertise in navigating the unique challenges of the cell and gene therapy sector, including evolving regulatory landscapes and specialized skill requirements
By partnering with Stirling Q&R, organizations can streamline their recruitment process and ensure they have the right talent to drive innovation and compliance in the rapidly advancing field of cell and gene therapies
GET IN TOUCH
